Literature DB >> 20631637

Deregulation of p27 and cyclin D1/D3 control over mitosis is associated with unfavorable prognosis in non-small cell lung cancer, as determined in 405 operated patients.

William Sterlacci1, Michael Fiegl, Wolfgang Hilbe, Herbert Jamnig, Wilhelm Oberaigner, Thomas Schmid, Florian Augustin, Jutta Auberger, Ellen C Obermann, Alexandar Tzankov.   

Abstract

INTRODUCTION: A large group of interacting molecular factors, involved in epithelial-mesenchymal transition, epidermal growth factor receptor (EGFR) signaling, and G1 mitotic phase, are shown to play an important role in cancerogenesis and progression of non-small cell lung cancer (NSCLC). Since success concerning potential correlations, structural and numeric gene aberrations, and biological risk assessment of these molecular factors are still lacking, combined analysis of a multitude of intertwined factors is currently a promising approach.
METHODS: Cyclins (D1, D2, D3, and E), p21, p27, EGFR, Snail, E-cadherin, beta-catenin, phosphatidylinositol-3' kinase, phosphatase and tensin homologue, phosphorylated Akt, and phosphorylated signal transducer, and activator of transcription-3 were analyzed by immunohistochemistry in 405 surgically resected NSCLC, using a standardized tissue microarray platform. In addition, the gene status of EGFR and cyclin D1 was examined by fluorescence in situ hybridization. Extensive clinical data were acquired, enabling detailed clinicopathologic correlation during a postoperative follow-up period of up to 14 years.
RESULTS: The protein overexpressions of nuclear p27, cyclin D1, cyclin D3, E-cadherin, and EGFR as assessed by immunohistochemistry were all associated with a significant reduction in overall survival time. In addition, cyclin D1 proved especially important, being the only independent molecular tumor-related factor with prognostic significance by multivariable analysis. In analogy to EGFR, recurrent numeric gene aberrations, particularly high-level amplifications, of cyclin D1 were obvious.
CONCLUSIONS: The results emphasize that deregulation of controlling factors of the early G1 phase is of significant oncogenic relevance and may represent a potential treatment target in NSCLC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20631637     DOI: 10.1097/JTO.0b013e3181e77efc

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  17 in total

1.  The impact of E-cadherin expression on non-small cell lung cancer survival: a meta-analysis.

Authors:  Ying Wu; Hong-Bing Liu; Ming Ding; Jian-Nan Liu; Ping Zhan; Xiao-Su Fu; Gan Lu
Journal:  Mol Biol Rep       Date:  2012-06-24       Impact factor: 2.316

2.  Detailed assessment of microvasculature markers in non-small cell lung cancer reveals potentially clinically relevant characteristics.

Authors:  Geoffrey Pomme; Florian Augustin; Michael Fiegl; Raoul A Droeser; William Sterlacci; Alexandar Tzankov
Journal:  Virchows Arch       Date:  2015-04-09       Impact factor: 4.064

3.  MET overexpression and gene amplification: prevalence, clinico-pathological characteristics and prognostic significance in a large cohort of patients with surgically resected NSCLC.

Authors:  William Sterlacci; Michael Fiegl; Mathias Gugger; Lukas Bubendorf; Spasenija Savic; Alexandar Tzankov
Journal:  Virchows Arch       Date:  2017-05-20       Impact factor: 4.064

4.  Exosomal miRNAs as biomarkers of recurrent lung cancer.

Authors:  Radha Munagala; Farrukh Aqil; Ramesh C Gupta
Journal:  Tumour Biol       Date:  2016-02-11

5.  Strong expression of cyclin B2 mRNA correlates with a poor prognosis in patients with non-small cell lung cancer.

Authors:  Shinogu Takashima; Hajime Saito; Naoko Takahashi; Kazuhiro Imai; Satoshi Kudo; Maiko Atari; Yoshitaro Saito; Satoru Motoyama; Yoshihiro Minamiya
Journal:  Tumour Biol       Date:  2013-12-28

6.  F-box protein FBXL2 exerts human lung tumor suppressor-like activity by ubiquitin-mediated degradation of cyclin D3 resulting in cell cycle arrest.

Authors:  B B Chen; J R Glasser; T A Coon; R K Mallampalli
Journal:  Oncogene       Date:  2011-10-24       Impact factor: 9.867

7.  Beneficial role of overexpression of TFPI-2 on tumour progression in human small cell lung cancer.

Authors:  Marion Lavergne; Marie-Lise Jourdan; Claire Blechet; Serge Guyetant; Alain Le Pape; Nathalie Heuze-Vourc'h; Yves Courty; Stephanie Lerondel; Julien Sobilo; Sophie Iochmann; Pascale Reverdiau
Journal:  FEBS Open Bio       Date:  2013-06-27       Impact factor: 2.693

8.  Prognostic and clinicopathological significance of downregulated E-cadherin expression in patients with non-small cell lung cancer (NSCLC): a meta-analysis.

Authors:  Yan-Long Yang; Ming-Wu Chen; Lei Xian
Journal:  PLoS One       Date:  2014-06-30       Impact factor: 3.240

9.  Prognostic value of MET, cyclin D1 and MET gene copy number in non-small cell lung cancer.

Authors:  Wenze Sun; Liping Song; Ting Ai; Yingbing Zhang; Ying Gao; Jie Cui
Journal:  J Biomed Res       Date:  2013-04-25

10.  Ki-67 labeling index affects tumor infiltration patterns of lung squamous cell carcinoma.

Authors:  Daisuke Masuda; Ryota Masuda; Tomohiko Matsuzaki; Naoko Imamura; Naohiro Aruga; Makiko Tanaka; Sadaki Inokuchi; Hiroshi Kijima; Masayuki Iwazaki
Journal:  Mol Med Rep       Date:  2015-09-24       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.